The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Rapamycin for longevity: opinion article
Open accessAbstract
From the dawn of civilization, humanity has dreamed of immortality. So why didn't the discovery of the anti-aging properties of mTOR inhibitors change the world forever? I will discuss several reasons, including fear of the actual and fictional side effects of rapamycin, everolimus and other clinically-approved drugs, arguing that no real side effects preclude their use as anti-aging drugs today. Furthermore, the alternative to the reversible (and avoidable) side effects of rapamycin/everolimus are the irreversible (and inevitable) effects of aging: cancer, stroke, infarction, blindness and premature death. I will also discuss why it is more dangerous not to use anti-aging drugs than to use them and how rapamycin-based drug combinations have already been implemented for potential life extension in humans. If you read this article from the very beginning to its end, you may realize that the time is now.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“When it is over-activated by nutrients and insulin, mTOR acts via S6K to inhibit insulin signaling, thereby causing insulin resistance [39-44].”
BackgroundRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease
Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J., Cullen, M. R., Glass, A., Keogh, J. P., Meyskens, F. L., Valanis, B., Williams, J. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605023341802 · Cited by 3,638
Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R. G., & Gluud, C. (2007) · JAMA · doi:10.1001/jama.297.8.842 · Cited by 2,275
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Influence of TOR kinase on lifespan in C. elegans
Vellai, T., Takacs-Vellai, K., Zhang, Y., Kovacs, A. L., Orosz, L., & Müller, F. (2003) · Nature · doi:10.1038/426620a · Cited by 1,057
Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967 · cited 1×
“For example, metformin extends lifespan not only in mice, but also in the worms, which do not suffer from human diseases [160, 161].”
BackgroundAntioxidants Accelerate Lung Cancer Progression in Mice
Sayin, V. I., Ibrahim, M. X., Larsson, E., Nilsson, J. A., Lindahl, P., & Bergo, M. O. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007653 · Cited by 867 · cited 1×
“Also disturbing is the finding that antioxidants accelerate cancer progression and promote metastasis [134-136].”
BackgroundmTOR inhibition improves immune function in the elderly
Mannick, J. B., Del Giudice, G., Lattanzi, M., Valiante, N. M., Praestgaard, J., Huang, B., Lonetto, M. A., Maecker, H. T., Kovarik, J., Carson, S., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009892 · Cited by 786
Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1
Um, S. H., D'Alessio, D., & Thomas, G. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.05.003 · Cited by 690
Cited by
Mitophagy: An Emerging Role in Aging and Age-Associated Diseases
Chen, G., Kroemer, G., & Kepp, O. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00200 · Cited by 359
Effect of rapamycin on aging and age-related diseases—past and future
Selvarani, R., Mohammed, S., & Richardson, A. (2021) · GeroScience · doi:10.1007/s11357-020-00274-1 · Cited by 290
Rapamycin in the context of Pascal's Wager: generative pre-trained transformer perspective
Generative Pre-trained Transformer, C., & Zhavoronkov, A. (2022) · Oncoscience · doi:10.18632/oncoscience.571 · Cited by 203
Boyajian, J. L., Ghebretatios, M., Schaly, S., Islam, P., & Prakash, S. (2021) · Nutrients · doi:10.3390/nu13124550 · Cited by 115
Macip, C. C., Hasan, R., Hoznek, V., Kim, J., Metzger, L. E., Sethna, S., & Davidsohn, N. (2023) · doi:10.1101/2023.01.04.522507 · Cited by 95
Macip, C. C., Hasan, R., Hoznek, V., Kim, J., Lu, Y. R., Metzger, L. E., Sethna, S., & Davidsohn, N. (2024) · Cellular Reprogramming · doi:10.1089/cell.2023.0072 · Cited by 95
“, 2013; Swindell, 2012), or through pharmaceutical interventions (Blagosklonny, 2019; Glossmann and Lutz, 2019).”
BackgroundElsayed, R., Elashiry, M., Liu, Y., Morandini, A. C., El-Awady, A., Elashiry, M. M., Hamrick, M., & Cutler, C. W. (2023) · Aging and disease · doi:10.14336/ad.2022.0623 · Cited by 40
Bhattacharya, K., Maiti, S., Zahoran, S., Weidenauer, L., Hany, D., Wider, D., Bernasconi, L., Quadroni, M., Collart, M., & Picard, D. (2022) · Nature Communications · doi:10.1038/s41467-022-33916-3 · Cited by 40
Birkisdóttir, M. B., Jaarsma, D., Brandt, R. M. C., Barnhoorn, S., van Vliet, N., Imholz, S., van Oostrom, C. T., Nagarajah, B., Portilla Fernández, E., Roks, A. J. M., et al. (2021) · Aging Cell · doi:10.1111/acel.13302 · Cited by 35
As predicted by hyperfunction theory, rapamycin treatment during development extends lifespan
Blagosklonny, M. V. (2022) · Aging · doi:10.18632/aging.203937 · Cited by 10
Self-citationWezeman, J., Darvas, M., Postupna, N., Klug, J., Mangalindan, R. S., Keely, A., Nguyen, K., Johnson, C., Rosenfeld, M., & Ladiges, W. (2024) · doi:10.1101/2024.01.26.577437 · Cited by 3
Metadata
- Authors
- Blagosklonny, M. V.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2019-10-04
- Volume
- 11
- Issue
- 19
- Pages
- 8048-8067
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W2978258070
- Cited by
- 205
- References
- 32
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.